The FDA approval of denileukin diftitox (Lymphir) marked a significant shift in this paradigm. As a first-in-class immunotoxin, it employs a dual-action mechanism: directly targeting interleukin-2 (IL ...

The use of bispecific antibodies (BsAb) before chimeric antigen receptor T-cell therapy (CAR-T) appeared to be a more optimal ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...

Burkitt's lymphoma is a rare and aggressive blood cancer characterized by a translocation of the MYC gene. It occurs most ...

A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...

In this MedPage Today video, Taylor Brooks, MD, of the Cleveland Clinic Cancer Institute, discusses real-world survival ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...

As the world observes World Lymphoma Awareness Day on September 15th, it 39;s a timely reminder of the ongoing battle against ...

Broadway actor Bret Hanna-Shuford known for Wicked has died at 46 from T-cell lymphoma Read ahead to know more about the ...

During a live event, Matthew Lunning, DO, interpreted long-term outcomes of the ZUMA-7 and TRANSFORM trials.

Trial data on epcoritamab plus rituximab-lenalidomide, a novel CELMoD agent, late-line CAR-T cell therapy, and selecting ...

A new clinical trial suggests that pairing bispecific antibodies and antibody-drug conjugates with CAR T-cell therapy may ...